GFAP

sGFAP as a biomarker in NMOSD 3:14
sGFAP as a biomarker in NMOSD
Friedemann Paul • 27 Apr 2023
Latest developments in Parkinson’s disease biomarkers 6:10
Latest developments in Parkinson’s disease biomarkers
Andrea Pilotto • 23 Mar 2023
GFAP and NfL as biomarkers in NMOSD 3:31
GFAP and NfL as biomarkers in NMOSD
Celia Oreja-Guevara • 24 Mar 2023
GFAP: a potential biomarker for progression in MS 1:31
GFAP: a potential biomarker for progression in MS
Elias Sotirchos • 27 Feb 2023
Serum biomarkers of brain atrophy in MS 4:59
Serum biomarkers of brain atrophy in MS
Ferhan Qureshi • 27 Feb 2023
The association between serum/CSF biomarkers and OCT measures in CIS patients 2:05
The association between serum/CSF biomarkers and OCT measures in CIS patients
Angela Vidal-Jordana • 26 Oct 2022
OCT measures association with serum/CSF biomarkers in CIS patients 2:00
OCT measures association with serum/CSF biomarkers in CIS patients
Jaume Sastre-Garriga • 28 Oct 2022
Evaluating the long-term cognitive effects of COVID-19 3:56
Evaluating the long-term cognitive effects of COVID-19
Jennifer Frontera • 3 Apr 2022
Promising biomarkers in MS: serum NfL & GFAP 0:42
Promising biomarkers in MS: serum NfL & GFAP
Caroline Pot • 27 Jun 2022
The potential of sNfL as an exploratory endpoint for MS trials 1:03
The potential of sNfL as an exploratory endpoint for MS trials
Jens Kuhle • 26 Jun 2022
Developments in biomarkers for MS susceptibility and prodrome 1:30
Developments in biomarkers for MS susceptibility and prodrome
Raphael Schneider • 2 Mar 2022
Emerging biomarkers in MS: CNTN1 and GFAP 4:13
Emerging biomarkers in MS: CNTN1 and GFAP
Charlotte Teunissen • 6 Oct 2021
sGFAP: a potential diagnostic and prognostic marker in FTD 2:21
sGFAP: a potential diagnostic and prognostic marker in FTD
Annakaisa Haapasalo • 16 Sep 2021
The content of VJNeurology is intended for healthcare professionals